Mesoblast (MESO) EBT (2014 - 2023)
Mesoblast (MESO) posted EBT of -$22.0 million for Q2 2023, down 17.77% sequentially from -$18.6 million in Q1 2023, and down 2.1% YoY from -$22.4 million in Q2 2022.
Mesoblast (MESO) EBT (2014 - 2023) Analysis & Trends
Mesoblast has reported EBT for 10 years, with the latest figure at -$22.0 million in Q2 2023.
- Quarterly EBT fell 2.1% year-over-year to -$22.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$82.1 million (up 10.36% YoY) and the FY2025 annual result came in at -$101.8 million, down 15.5% from the prior year.
- EBT fell to -$22.0 million in Q2 2023 per MESO's latest filing, from -$18.6 million in the prior quarter.
- Over five years, EBT peaked at -$7.4 million in Q3 2019 and troughed at -$35.9 million in Q2 2020.
- A 5-year average of -$22.9 million and a median of -$23.3 million in 2019 frame the typical range for EBT.
- The sharpest annual moves came in 2019 and 2020: EBT surged 63.3% in 2019, then slumped 240.8% in 2020.
- Over 5 years, EBT stood at -$26.9 million in 2019, then increased by 4.6% to -$25.6 million in 2020, then declined by 1.59% to -$26.0 million in 2021, then gained by 5.64% to -$24.6 million in 2022, then increased by 10.58% to -$22.0 million in 2023.
- According to Business Quant data, EBT over the past three periods registered -$22.0 million, -$18.6 million, and -$24.6 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -21.96 Mn |
| Mar 31, 2023 | -18.65 Mn |
| Dec 31, 2022 | -24.56 Mn |
| Sep 30, 2022 | -16.94 Mn |
| Jun 30, 2022 | -21.51 Mn |
| Mar 31, 2022 | -21.35 Mn |
| Dec 31, 2021 | -26.03 Mn |
| Sep 30, 2021 | -22.71 Mn |
| Jun 30, 2021 | -22.13 Mn |
| Mar 31, 2021 | -26.61 Mn |
| Dec 31, 2020 | -25.62 Mn |
| Sep 30, 2020 | -25.27 Mn |
| Jun 30, 2020 | -35.87 Mn |
| Mar 31, 2020 | -17.22 Mn |
| Dec 31, 2019 | -26.85 Mn |
| Sep 30, 2019 | -7.42 Mn |
| Jun 30, 2019 | -23.90 Mn |
| Mar 31, 2019 | -27.18 Mn |
| Dec 31, 2018 | -27.47 Mn |
| Sep 30, 2018 | -20.21 Mn |